|
|
|
International Clinical Trials
|
With organisations operating in a global environment in a digital age,
no business can afford to fall behind with their site staff training
programme. Brendan Buckley at Firecrest Clinical explains how a hybrid
model of tailored, focused meetings using web-based platforms can
ensure that every member of the study team is adequately informed,
regardless of where they are in the world
A hybrid model of coordinated investigator site training ensures that
appropriate training is given to site staff and puts all sites on an
equal footing globally.
The clinical trial industry, like many others, is undergoing a period
of change, and with clinical studies becoming increasingly complex, so
too are the day-to-day demands on site staff, requiring a more
efficient and effective means of managing studies at sites.
The industry is also witnessing a shift from the longestablished and
deeply ingrained model of global investigator meetings, initiating and
training site staff at the beginning of a study. Designed to introduce
principal investigators (PIs) to the trial objectives and protocol
training, investigator meetings are usually held six months in advance
of site initiation, potentially placing an unfair expectation on site
staff to retain and execute training received far in advance of their
actual participation in the study.
A BETTER WAY TO LEARN
The current design of a typical investigator meeting is not conducive
to interactive learning. Overused and repetitive presentation methods
are never going to fully engage site staff in a clinical study. One
only has to use the term ‘death by PowerPoint’ in front of a group of
study personnel to be met with a sea of nodding heads. In addition,
there is the issue of language barriers for certain delegates whose
native language is not English. Many industry professionals have
undoubtedly been in the typical investigator meeting scenario where
they turn to converse with another delegate at a session or dinner,
only to discover that their English is extremely limited. With English
being internationally accepted as ‘the language of clinical research,’
it goes without saying that many individuals attending an investigator
meeting delivered in English cannot be considered to be effectively
trained on a study protocol and are perhaps at an immediate
disadvantage on the study. The possibility of the localisation of
training into several languages means that this barrier can be swiftly
and effectively overcome, putting all sites on an equal footing.
A HYBRID APPROACH TO MEETINGS
While it is true that the value of investigator meetings can never be
underestimated, when it comes to industry networking and peer-to-peer
relationship building, a new model is emerging to address the
acknowledged inadequacies of the traditional investigator meeting from
a training perspective.
Ideally, what the industry needs is a hybrid model of training via
shorter, regional and more PI-focused meetings, combined with
web-based, certifiable training for site staff at key milestones
throughout the study.
A PI attends an investigator meeting to absorb the trial objectives and
drug compound information, but in most cases should not be asked to sit
through hours of lengthy vendor presentations, which are of more
relevance to the site staff. Neither is it practical or possible for
all site staff participating on a study to attend an investigator
meeting to learn first-hand from the presenting vendors. Therefore,
those that cannot be there are at somewhat of a disadvantage when they
are initiated onto the study. Can a sponsor ever be confident that site
staff across a global study are all trained and equipped to execute and
report study procedures to the same high standard?
Simply put, each group of study personnel receives a tailored initiation to the study to meet their separate needs:
- PIs complete a protocol-specific training module in advance of a
regional investigator meeting, thus reducing the time required to sit
through lengthy presentations that are of little interest to the PI
- Monitoring teams receive in-depth, face-to-face training as a
separate group, including detailed instruction on the introduction of
site staff to a web-based interactive system
- Site staff perform online training immediately prior to their scheduled site initiation visit date
CUSTOMISED STUDY PORTAL
A centralised web-based study portal can provide all participants with
one username, one password and one URL to access customised training
modules designed specifically for their role on the study. In addition
to training modules, the site can host a centrally-located operations
manual for the study, as well as detailed immediate instructions
individualised for each participant and each step of the trial. Such a
site can facilitate seamless access to EDC and IWRS as well as
documents, reports and study metrics, with additional features such as
online meeting centre functionality to improve study communication
globally. It acts as a central repository for training, essential trial
documentation, as well as step-by-step, point-of-care procedural
information. Live data feeds to the study portal deliver regular
updates to all users on patient recruitment, randomisation, top
recruiting sites, and so on. When real-time coordination of study
personnel is required, the study portal’s online meeting feature can
act as an interactive digital meeting site, eliminating the need for
travel.
What does this mean? One web-based study portal linking all the various
clinical trial management systems and tools for the study, thereby
eliminating the burden on site staff to get to grips with several
different technologies and complex user menus.
TRIAL IN YOUR HAND
Recent and rapid advancements in mobile technology now mean that, more
than ever before, site staff can access the information they need when
they are away from their desktop and by their patients’ sides. Mobile
devices and applications ensure that a study portal can be a portable
platform enabling site staff to enter real-time data as they receive
it, reducing the dependency on cumbersome and antiquated paper-based
systems. Imagine the potential for the speed of a clinical study to be
increased and the number of careless data errors to be reduced, all
ultimately facilitating the complicated voyage of clinical compounds to
market.
IMPROVED TRIAL PERFORMANCE
The bedrock of clinical trial conduct is that the protocol must be
meticulously and faithfully applied; to this end it is paramount that
training is delivered to sites in close proximity to the date of site
initiation. This strategic method significantly improves retention and
individual performance in key aspects of the trial. Current industry
trends demonstrate that clinical trials deploying such web-based and
mobile technologies at their sites are reporting increased patient
recruitment in addition to reduced protocol deviations and data
queries. With typical data queries costing in the region of $80 to $100
per query, these reported improvements are of great significance to
sponsor companies who are under increasing pressure to streamline
overall clinical trial costs. Consider the current issues within the
investigative landscape:
- Burdensome investigator meeting design
- Language barriers for study personnel
- Outdated and unimaginative training format
- Global communication inefficiencies
By improving communications at the site level, compliance, consistency
and quality of execution throughout the life of the study is greatly
enhanced. Requiring study staff to login to gain access, for example,
not only secures data from unauthorised users, but provides the project
manager with a record of each staff member’s ongoing interaction with
the study portal.
Each team member can be tracked to ensure training has been performed
and is understood, procedures are followed, timelines are met, and
study parameters are maintained. This also allows the study manager to
analyse performance on a site-by-site basis – to determine the
percentage of sites that have reached a particular milestone, for
example – and to guarantee compliance to the requirements set by
regulatory bodies.
With the hybrid model of tailored, coordinated training delivered to
trial personnel groups, along with localised, stepby- step instructions
for all site staff across a global study, the variances in study
procedure execution and data reporting, which are hampering clinical
trial efficiencies, can be effectively overcome.
CONCLUSION
In a global environment and a digital age, reliance on outdated methods
of training and communication hinders a clinical study’s chance of
success. By placing training, operations information and data
collection on a web-based platform, every member of the study team –
from a CRA in a far-flung clinic to the study sponsor – can get exactly
the information they need, whenever they need it, regardless of where
they are in the world.
Combining these capabilities with focused regional face-toface meetings
is proving to be one of the best methods for significantly reducing
protocol deviations and data queries, lowering overall trial costs and
greatly improving the chance of investigational products proceeding to
the next phase of clinical research.
|
Read full article from PDF >>
|
 |
 |
 |
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|

 |
Industry Events |
 |
CPhI China
26-28 June 2012, Shanghai, China
China's pharmaceutical market is forecasted to become the world's second largest pharma market in 2011. As the Healthcare Reform is progressing into an essential stage, China presents great opportunities for all international pharmaceutical companies to explore and benefit from.
More info >> |
|
 |
News and Press Releases |
 |
Acquisition of Eisai Machinery approved
Bosch Packaging Technology continues to grow: Bosch finalized the acquisition of the machinery business companies (hereafter Eisai Machinery) of Eisai Co., Ltd., one of the leading Japanese pharmaceutical companies based in Tokyo. The transaction has been approved by the antitrust authorities without further restrictions. The entire share and equity interest of Eisai Machinery is transferred to the Bosch Group. Eisai’s machinery business is specialized in the manufacture, sales and export of inspection equipment as well as pharmaceutical machinery and packaging materials. In 2010, Eisai Machinery generated sales of around 76 million euros (8.6 bn JPY).
More info >> |
|
|